[Medical treatments for breast cancer].
Breast carcinoma is no longer considered as a local disease. So, surgery and radiotherapy could be insufficient to control undetectable distant micro-metastasis. Naturally, systemic medical procedures have been extended from metastatic stages to adjuvant and neo-adjuvant settings. The double sensitivity to both hormonal and chemical agents give to clinicians a large number of putative choices. Recent discovery of membrane receptor-targeted monoclonal antibodies enriched our armentarium.
Roché
Henri
H
Institut Claudius Regaud, 31052 Toulouse. roche@icr.fnclcc.fr
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy*; D003131:Combined Modality Therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010052:Ovariectomy; D010347:Patient Care Planning; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D004965:Estrogen Antagonists; D011960:Receptors, Estrogen